Loading...
Loading...
Browse all stories on DeepNewz
VisitDEA Increases Vyvanse Production Limit by 24% to Address ADHD Drug Shortage
Sep 4, 2024, 11:15 AM
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the medication in the United States. This decision aims to mitigate the impact of the current drug shortage affecting ADHD treatment. The US is allowing 24% more production of Vyvanse and its generic rivals to address treatment shortages.
View original story
Markets
Yes • 50%
No • 50%
FDA official announcements and approvals
Yes • 50%
No • 50%
Takeda Pharmaceutical's official financial reports
No • 50%
Yes • 50%
Official announcements from the DEA, Takeda Pharmaceutical, and major news outlets
0-5% • 25%
16% or more • 25%
11-15% • 25%
6-10% • 25%
Retail pharmacy pricing data and reports
31% or more • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Takeda Pharmaceutical's official financial reports
Takeda Pharmaceutical • 25%
Teva Pharmaceutical • 25%
Eli Lilly • 25%
Other • 25%
Market share reports from industry analysts and market research firms